NCT06542276
Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED
Enrolling by Invitation
NAAges 25–65InterventionalTreatmentDunes Eye ConsultantsInvestigator-initiated
~30 participants
Updated 2024-08-12 on ClinicalTrials.gov
What's tested:Thermal Vectored Pulsation
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Subjects discontinuing Topical Immunomodulator use
Measured over 3 months
Conditions
Where it's being run
1 sites across 1 statesSouth Dakota1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
No prior history of meibomian gland treatment procedures LipiFlow, TearCare, or I-Lux
lifitegrast or cyclosporine eye drops daily for a period of at least one year but not exceeding five years
Meibograpy documneted retention of at least 50% of meibomian glands.
Exclusion
evidence of meibomian gland dropout exceeding 50%
ocular rosacea,
ocular surgery within the preceding three months
prior in-office thermal meibomian gland treatment
ocular trauma within preceding three months
ocular herpetic infection
chronic or recurrent inflammation
eyelid abnormalities affecting lid function ocular surface abnormalities compromising corneal integrity (eg, epithelial basement membrane dystrophy, corneal burn)
pregnant
What this trial measures
- Number of Subjects discontinuing Topical Immunomodulator use3 months
OSDI, TBUT, Tear Osmolarity, Meibomian gland expression quantity, TM